Showing 441-450 of 1560 results for "".
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
https://reachmd.com/programs/project-oncology/from-infusion-to-injection-can-subcutaneous-delivery-match-intravenous-standards-in-oncology/36400/Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
https://reachmd.com/programs/cme/effective-monitoring-and-management-of-adverse-effects-in-metastatic-escc/29792/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
https://reachmd.com/programs/cme/distinguishing-between-anti-pd-1-agents-in-escc-combination-therapies/29790/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.Make Filler Great Again
https://modernaesthetics.com/ma-issues-index/2025-mar-apr/make-filler-great-again-restoring-balance-function-and-trust/36063/Restoring balance, function, and trustUnderstanding Who Joined COVID-19 Vaccine Trials and Why
https://reachmd.com/programs/clinicians-roundtable/understanding-who-joined-covid-19-vaccine-trials-and-why/36416/Fat, Exercise and Cholesterol
https://reachmd.com/programs/lipid-luminations/fat-exercise-and-cholesterol/6542/Host Dr. Alan Brown discusses fat, exercise and cholesterol with Dr. Harold Bays, medical director and president of Louisville Metabolic and Atherosclerosis Research Center, an independent research center. They look at the properties of adipose tissue — what Dr. Bays calls adiposopathy, or "sick fatDifferentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
https://reachmd.com/programs/cme/differentiating-first-line-treatment-selection-combination-immunotherapy-and-chemotherapy-regimens-for-metastatic-escc/29167/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
https://reachmd.com/programs/cme/strategies-for-navigating-first-line-treatment-selection-in-metastatic-escc/33029/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.Reacting to RET Inhibitors: A Look at Progression & the Future
https://reachmd.com/programs/project-oncology/reacting-to-ret-inhibitors-a-look-at-progression-the-future/12429/One starting on a RET inhibitor, what do patients need to know about treatment progression into the future?